Welcome to PASPORT: A global clinical research program to advance patient care
PASPORT (PASireotide clinical trial PORTfolio) is a large-scale, worldwide clinical trial program evaluating pasireotide in patients with:
Pituitary tumors (including registration studies in acromegaly and Cushing’s disease)
Rare neuroendocrine tumors of the pituitary and pancreas
Other solid tumors
The medical management of neuroendocrine tumors and pituitary adenomas can present significant therapeutic challenges. Pasireotide (SOM230) is an investigational somatostatin analogue with a multireceptor- targeting profile.1 PASPORT will assess the efficacy and safety of pasireotide in the treatment of patients with these often difficult-to-treat tumors and tumor-associated disorders.
Pasireotide and pasireotide LAR are investigational agents whose safety and efficacy for these indications and investigational uses have not been established. There is no guarantee that pasireotide or pasireotide LAR will become commercially available for these indications and uses.
Reference: 1. Bruns C, et al. Eur J Endocrinol. 2002;146(5):707-716.
Disclaimer: This is a global web site for Pasport™ providing general information for healthcare professionals from all countries. The information on this site is not country-specific and may contain program information that is different from where you practice. Please contact your local Novartis representative for the latest information specific to your country.